Citations

Mayo Clinic

Showing 10 of 108572 citations.

The Bleeding Sunflower Polyp: A Rare Sequelae of Over-the-Scope Clip Placement
Ramkissoon, Resham­ , Song, Louis M. Wong Kee , Coelho–Prabhu, Nayantara

American Journal of Gastroenterology | February 4, 2024 | Volume: 119 | Issue: 6 | Pages: 1015-1015

10.14309/ajg.0000000000002692 | PMID 38310347 Get It

A Call to Action: Urgently Strengthening the Future Physician-Scientist Workforce in Infectious Diseases
Swartz, Talia H. , Apewokin, Senu , Carpenter, Stephen M. , Chakraborty, Rana , Dennis, Ann M. , Houpt, Eric R. , Surana, Neeraj K. , Zerr, Danielle M. , Pirofski, Liise-anne , Swartz, Talia H , Pirofski, Liise‐anne

The Journal of Infectious Diseases | February 4, 2024 | Volume: 229 | Issue: 3 | Pages: 625-629

10.1093/infdis/jiad610 | PMID 38309710 Get It

Abstract Infectious diseases (ID) research is vital for global public health, typically led by physician-scientists. This Perspective addresses challenges in the ID workforce and suggests solutions. Physician-scientists have made key discoveries that have significantly impacted human health. The importance of ID research in understanding diseases, leading to treatments and vaccines, is emphasized, along with the need to address persistent and new infections, antimicrobial resistance, and threats like HIV and influenza. The paper analyzes the physician-scientist workforce's struggles, including funding, training, and research-practice integration gaps. We suggest increased funding, better training, and mentorship, more collaborative and interdisciplinary research, and improved recognition systems. The article stresses the urgency of supporting physician-scientists in ID, advocating for proactive prevention and preparedness, and calls for immediate action to enhance ID research and care.
Safety of the immediate use of nonsteroidal anti-inflammatory drugs after adult craniotomy for tumor
Perez, Jennifer L. , Naylor, Ryan M. , Harrison, Daniel , Knowles, Kyelin, Link, Michael J., Celda, María Peris, Meyer, Fredric B. , Harrison, Daniel Jeremiah, Peris Celda, Maria, Van Gompel, Jamie, Bauman, Megan M. J. , Burns, Terry C. , Lanzino, Giuseppe , Link, Michael J. , Gompel, Jamie J. Van , Parney, Ian F.

Journal of Neurosurgery | February 3, 2024 | Volume: 141 | Issue: 1 | Pages: 117-122

10.3171/2023.11.jns231600 | PMID 38306640 Get It

OBJECTIVE Poor pain control has a negative impact on postoperative recovery and patient satisfaction. However, overzealous pain management, particularly with opioids, can confound serial neurological assessments, increase morbidity, and predispose patients to long-term dependence. Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in treating postoperative pain and can limit opioid intake, but their use has been limited in patients undergoing craniotomy for brain tumor resection due to concerns of an increased hemorrhage risk. Herein, the authors aim to 1) address the safety of NSAID use in the immediate postoperative setting and 2) determine whether NSAID administration decreases opioid use following craniotomy for tumor resection in adult patients. METHODS The authors conducted a retrospective cohort study of patients 18 years and older with an estimated glomerular filtration rate ≥ 60 ml/min/body surface area who had undergone craniotomy for tumor resection at their institution between 2019 and 2021. NSAID use in the first 48 hours following surgery was recorded. Primary outcomes were postoperative hemorrhage requiring a return to the operating room before hospital discharge and within 30 days of surgery. Secondary outcomes were more-than-minimal hemorrhage that did not require reoperation, acute kidney injury, and total opioid use within 48 hours after craniotomy. RESULTS Among 1765 reviewed patient records, 1182 were eligible for inclusion in this analysis. Amid these records were 114 patients (9.6%) who had received at least one dose of an NSAID within 48 hours of their craniotomy. Four (0.3%) patients experienced bleeding requiring a return to operating room, one of whom was from the NSAID-treated group (RR 3.12, 95% CI 0.33–29.77, p = 0.30). No significant difference in nonoperative intracranial hemorrhage (RR 1.34, 95% CI 0.54–3.35, p = 0.53), postoperative acute kidney injury, or clinically significant extracranial bleeding was found between the NSAID and no-NSAID groups. Patients in the NSAID group had significantly higher oral morphine equivalent use (median 68 vs 30, p < 0.001). CONCLUSIONS Postoperative NSAID use following craniotomy for tumor resection was not associated with an increased risk of hemorrhage requiring a return to the operating room. The authors noted higher opioid use in the patients treated with NSAIDs, which may reflect underlying reasons for the decision to treat patients with NSAIDs in the immediate postoperative period. These data warrant further investigation of NSAIDs as a safe, opioid-sparing postoperative pain management strategy in patients with normal kidney function who are undergoing intracranial tumor resection.
“Follow‐up in a few days”: Limitations to primary care access among older adults following emergency department discharge
Gettel, Cameron J. , Hartzheim, John, Chera, Tonya, Galske, James , Cameron, Lauren , Bellolio, Fernanda , Berrin, Lily Leitner, Bellolio, M Fernanda , Venkatesh, Arjun K.

Journal of the American Geriatrics Society | February 3, 2024 | Volume: 72 | Issue: 5 | Pages: 1528-1531

10.1111/jgs.18791 | PMID 38308394 Get It

The Primary Risk Factors for Season‐Ending Injuries in Professional Basketball Are Minutes Played Per Game and Later Season Games
Menon, Sanjit , Morikawa, Landon , Tummala, Sailesh V. , Buckner‐Petty, Skye , Chhabra, Anikar , Chhabra, Anikar , Tummala, Sailesh V

Arthroscopy | February 3, 2024 | Volume: 40 | Issue: 9 | Pages: 2468-2473

10.1016/j.arthro.2024.01.018 | PMID 38311270 Get It

Purpose To determine the incidence rates and associated risk factors of season‐ending injuries (SEIs) in the National Basketball Association (NBA) from the 2015‐20 seasons. Methods Publicly available records of active NBA players between the 2015‐16 and 2020‐21 seasons were reviewed to identify players with an SEI. In this study, SEI was classified as any injury that resulted in failure to return at least 5 games before the end of the team’s game schedule. Injury data from the 2019‐20 NBA season, shortened because of the coronavirus disease 2019 pandemic, were omitted. The primary outcome was the incidence of SEIs reported per 1,000 game exposures (GEs). Player demographics, basketball statistics, injury characteristics, and timing of injury were recorded. Secondary analysis, including bivariate analysis and multivariate logistic regression, was performed to investigate factors associated with having an SEI. Results In total, 196 players (15.6% of all players) sustained a combined 238 SEIs between the 2015‐16 and 2020‐21 seasons, indicating a rate of 1.74 SEIs per 1,000 GEs. When characterized by body part, knee injuries were found to be the most frequent SEI, at a rate of 0.47 injuries per 1,000 GEs. Accounting for potential confounders, having an SEI was significantly associated with more minutes per game played (odds ratio, 1.06, 95% confidence interval, 0.99‐1.01, P < .001). Conclusions SEIs occurred in 15.6% of players in this study, with an overall rate of 1.74 SEIs per 1,000 GEs. The most significant risk factor associated with injury was minutes per game. SEI was more likely to occur in the third and fourth quartiles of the NBA season than in the first or second quartile. Level of Evidence : Level III, retrospective comparative prognostic investigation.
Resolving signal drift in the wall‐mounted camera of the RGSC system
Park, Jeong‐Hoon , Gagneur, Justin D., Chungbin, Suzanne J., Rong, Yi , Lim, Seng Boh , Chan, Maria F. , Park, Jeonghoon , Rong, Yi

Journal of Applied Clinical Medical Physics | February 2, 2024 | Volume: 25 | Issue: 3 | Pages: No page available

10.1002/acm2.14291 | PMID 38306504 Get It

AbstractPurposeTo present a modified calibration method to reduce signal drift due to table sagging in Respiratory Gating for Scanner (RGSC) systems with a wall‐mounted camera.Materials and MethodsApproximately 70 kg of solid water phantoms were evenly distributed on the CT couch, mimicking the patient's weight. New calibration measurements were performed at 9 points at the combination of three lateral positions, the CT isocenter and ±10 cm laterally from the isocenter, and three longitudinal locations, the CT isocenter and ±30 cm or ±40 cm from the isocenter. The new calibration was tested in two hospitals.ResultsImplementing the new weighed calibration method at the extended distance yielded improved results during the DIBH scan, reducing the drift to within 1 from 3 mm. The extended calibration positions exhibited similarly reduced drift in both hospitals, reinforcing the method's robustness and its potential applicability across all centers.ConclusionThis proposed solution aims to minimize the systematic error in radiation delivery for patients undergoing motion management with wall‐mounted camera RGSC systems, especially in conjunction with a bariatric CT couchtop.
Patient-derived organoids recapitulate glioma-intrinsic immune program and progenitor populations of glioblastoma
Watanabe, Fumihiro , Hollingsworth, Ethan W. , Bartley, Jenna M. , Wisehart, Lauren, Desai, Rahil , Hartlaub, Annalisa M., Hester, Mark E. , Schiapparelli, Paula , Quiñones‐Hinojosa, Alfredo , Imitola, Jaime , Desai, Rahil, Imitola, Jaime

PNAS Nexus | February 2, 2024 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/pnasnexus/pgae051 | PMID 38384384 Get It

Abstract Glioblastoma multiforme (GBM) is a highly lethal human cancer thought to originate from a self-renewing and therapeutically-resistant population of glioblastoma stem cells (GSCs). The intrinsic mechanisms enacted by GSCs during 3D tumor formation, however, remain unclear, especially in the stages prior to angiogenic/immunological infiltration. In this study, we performed a deep characterization of the genetic, immune, and metabolic profiles of GBM organoids from several patient-derived GSCs (GBMO). Despite being devoid of immune cells, transcriptomic analysis across GBMO revealed a surprising immune-like molecular program, enriched in cytokine, antigen presentation and processing, T-cell receptor inhibitors, and interferon genes. We find two important cell populations thought to drive GBM progression, Special AT-rich sequence-binding protein 2 (SATB2+) and homeodomain-only protein homeobox (HOPX+) progenitors, contribute to this immune landscape in GBMO and GBM in vivo. These progenitors, but not other cell types in GBMO, are resistant to conventional GBM therapies, temozolomide and irradiation. Our work defines a novel intrinsic immune-like landscape in GBMO driven, in part, by SATB2+ and HOPX+ progenitors and deepens our understanding of the intrinsic mechanisms utilized by GSCs in early GBM formation.
Venous and arterial thrombosis in patients with VEXAS syndrome
Kusne, Yael , Ghorbanzadeh, Atefeh , Dulau-Florea, Alina, Alcedo, Pedro E., Nghiem, Khanh, Ferrada, Marcela A. , Hines, Alexander , Quinn, Kaitlin A. , Panicker, Sumith R. , Reichard, Kaaren K. , Darden, Ivana, Goodspeed, Wendy, Durrani, Jibran , Wilson, Lorena, Olteanu, Horatiu , Lasho, Terra, Kastner, Daniel L. , Mangaonkar, Abhishek A. , Braylan, Raul C. , Beck, David B. , Patnaik, Mrinal M. , Young, Neal S. , Grayson, Peter C. , Panicker, Sumith R , Durrani, Jibran , Olteanu, Horatiu , Warrington, Kenneth J , Patnaik, Mrinal , Casanegra, Ana I , Houghton, Damon E , Groarke, Emma M , Quinn, Kaitlin A , Ferrada, Marcela A , Ghorbanzadeh, Atefeh , Shalhoub, Ruba N. , Ombrello, Amanda K. , Warrington, Kenneth J. , Go, Ronald S. , Calvo, Katherine R. , Casanegra, Ana I. , Koster, Matthew J. , Wu, Colin O. , Kanthi, Yogendra , Patel, Bhavisha A. , Houghton, Damon E.

Blood | February 2, 2024 | Volume: 143 | Issue: 21 | Pages: 2190-2200

10.1182/blood.2023022329 | PMID 38306657 Get It

Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, caused by somatic mutations in UBA1, is an autoinflammatory disorder with diverse systemic manifestations. Thrombosis is a prominent clinical feature of VEXAS syndrome. The risk factors and frequency of thrombosis in VEXAS syndrome are not well described, due to the disease’s recent discovery and the paucity of large databases. We evaluated 119 patients with VEXAS syndrome for venous and arterial thrombosis and correlated their presence with clinical outcomes and survival. Thrombosis occurred in 49% of patients, mostly venous thromboembolism (VTE; 41%). Almost two-thirds of VTEs were unprovoked, 41% were recurrent, and 20% occurred despite anticoagulation. The cumulative incidence of VTE was 17% at 1 year from symptom onset and 40% by 5 years. Cardiac and pulmonary inflammatory manifestations were associated with time to VTE. M41L was positively associated specifically with pulmonary embolism by univariate (odds ratio [OR]: 4.58, confidence interval [CI] 1.28-16.21, P = .02) and multivariate (OR: 16.94, CI 1.99-144.3, P = .01) logistic regression. The cumulative incidence of arterial thrombosis was 6% at 1 year and 11% at 5 years. The overall survival of the entire patient cohort at median follow-up time of 4.8 years was 88%, and there was no difference in survival between patients with or without thrombosis (P = .8). Patients with VEXAS syndrome are at high risk of VTE; thromboprophylaxis should administered be in high-risk settings unless strongly contraindicated.
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis
Feagan, Brian G. , Ott, Elyssa , Gasink, Christopher , Godwin, Bridget, Marano, Colleen , Ye, Miao , Loftus, Edward V. , Sandborn, William J. , Loftus, Edward V , Danese, Silvio , Ghosh, Subrata , Ma, Tony Xuyen , Danese, Silvio , Abreu, María T. , Sands, Bruce E

Journal of Crohn's and Colitis | February 2, 2024 | Volume: 18 | Issue: 7 | Pages: 1091-1101

10.1093/ecco-jcc/jjae013 | PMID 38310565 Get It

Abstract Background and Aims Previously published long-term safety data reported a favourable ustekinumab safety profile for the treatment of inflammatory bowel disease [IBD]. We present the final cumulative safety data from pooled ustekinumab IBD phase 2/3 clinical studies through 5 years in Crohn’s disease [CD] and 4 years in ulcerative colitis [UC]. Methods In phase 3 studies, patients received a single intravenous placebo or ustekinumab [130 mg or ~6 mg/kg] induction dose followed by subcutaneous maintenance doses of placebo or ustekinumab [90 mg q8w or q12w]. Analyses included all patients who received one dose of study treatment and included patients who were biologic-naïve and patients with a history of biologic failure. Safety outcomes are summarized and presented using number of events per 100 patient-years of follow-up and corresponding 95% confidence intervals. Results In this final pooled safety analysis, 2575 patients were treated with ustekinumab with 4826 patient-years of follow-up. Rates of key safety events, including major adverse cardiac events and malignancies, were similar between placebo and ustekinumab or not higher for ustekinumab. Opportunistic infections, including tuberculosis, and malignancies were reported infrequently. Rates of key safety events in the IBD group were no higher in the ustekinumab group than in the placebo group for both patients who were biologic-naïve or who had a history of biologic failure. No lymphomas or cases of posterior reversible encephalopathy syndrome [formerly known as reversible posterior leukoencephalopathy syndrome] were reported. Conclusion The final cumulative ustekinumab safety data through 5 years in CD and 4 years in UC demonstrated favourable safety compared to placebo and continue to support the well-established safety profile across all approved indications. Clinical trials.gov numbers NCT00265122, NCT00771667, NCT01369329, NCT01369342, NCT01369355, NCT02407236
NAFLD IN CHILDREN: A SINGLE‐CENTER EXPERIENCE
Marcellini, Matilde, Devito, R, Sartorelli, MR, Angulo, Paul, Nobili, Valério , Devito, R, Ciampalini, Paolo , Comparcola, Donatella , Sartorelli, Maria Rita , Piemonte, Fiorella

Journal of Pediatric Gastroenterology and Nutrition | February 2, 2024 | Volume: 42 | Issue: 5 | Pages: No page available

10.1002/j.1536-4801.2006.tb01933.x Get It